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Abstract: The effectiveness of anticancer agents may be hindered by low solubility in water, 
poor permeability, and high efflux from cells. Nanomaterials have been used to enable drug 
delivery with lower toxicity to healthy cells and enhanced drug delivery to tumor cells. Different 
nanoparticles have been developed using different polymers with or without surface modifica-
tion to target tumor cells both passively and/or actively. Polylactide-co-glycolide (PLGA), a 
biodegradable polyester approved for human use, has been used extensively. Here we report on 
recent developments concerning PLGA nanoparticles prepared for cancer treatment. We review 
the methods used for the preparation and characterization of PLGA nanoparticles and their 
applications in the delivery of a number of active agents. Increasing experience in the field of 
preparation, characterization, and in vivo application of PLGA nanoparticles has provided the 
necessary momentum for promising future use of these agents in cancer treatment, with higher 
efficacy and fewer side effects.
Keywords: nanotechnology, polymeric nanocarriers, targeting, anticancer agents, surface 
modification
Introduction
Recent developments in nanotechnology have enabled new research strategies to 
  flourish in the field of drug delivery. There has been considerable interest in developing 
nanoparticles as effective drug carriers.1 For pharmaceutical purposes, nanoparticles 
are defined as solid colloidal particles ranging in size from 10 nm to 400 nm. They 
consist of macromolecular materials in which the active agent (drug or biologically 
active material) is dissolved, entrapped, and/or encapsulated, or to which the active 
agent is adsorbed or attached.2
Drug delivery has been improved with the translation of several nanoscale drug 
delivery systems into the clinic, although the full potential of these systems is only 
now starting to be explored. Nanoscale drug delivery systems have shown the ability 
to encapsulate a variety of therapeutic agents, such as small molecules (hydrophilic 
and/or hydrophobic), peptide protein-based drugs, and nucleic acids. By encapsulat-
ing these molecules inside a nanocarrier, the solubility and stability of drugs can be 
improved, providing an opportunity to re-evaluate the therapeutic potential of drugs 
previously discounted because of poor pharmacokinetics.3
The diversity of drug delivery systems allows nanoparticles to be developed with 
a diverse array of shapes, sizes, and components, enabling them to be tailored for 
specific applications. However, the primary consideration when designing any drug 
delivery system is to control the drug concentration in the therapeutic window, while International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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reducing side effects and improving patient compliance. This 
allows effective treatment cycles to be maintained, and at the 
same time reduces damage to healthy cells and minimizes 
the recovery period.4–6
Langer and Folkman were the first to demonstrate the 
controlled release of macromolecules using polymers, which 
enabled the development of antiangiogenic drug delivery 
systems for cancer therapy and opened up new areas for the 
delivery of macromolecules.7
Polymeric nanoparticles provide significant flexibility in 
design because different polymers from synthetic or natural 
sources can be used. Polymeric nanoparticles may represent 
the most effective nanocarriers for targeted drug delivery. 
Some common polymers used for nanoparticle formation 
include polylactide-co-glycolide (PLGA), polylactic acid, 
dextran, and chitosan. Biodegradable polymers are typically 
degraded into oligomers and individual monomers, which 
are metabolized and removed from the body via normal 
pathways.8–10
Degradation and drug release kinetics can be precisely 
controlled by the physicochemical properties of the polymer, 
such as molecular weight, polydispersity index, hydropho-
bicity, and crystallinity. In general, drugs can be released in 
a controlled manner following Fickian kinetics due to drug 
diffusion through the polymeric matrix, or be triggered in 
response to environmental stimuli or released in the course 
of chemical degradation. The nanoparticle surface may be 
sterically stabilized by grafting, conjugating, or adsorbing 
hydrophilic polymers, such as polyethylene glycol (PEG), 
to its surface, which can reduce hepatic uptake and improve 
the circulation half-life of the nanoparticles.11,12 PLGA is 
one of the most commonly used degradable polymers and is 
discussed extensively here.
Properties of PLGA
PLGA has generated tremendous interest due to its excellent 
biocompatibility, biodegradability, and mechanical strength 
(Figure 1).13 PLGA can be synthesized by a polycondensation 
reaction or via ring-opening polymerization of cyclic diesters. 
Ring-opening polymerization is currently the preferred 
method for the synthesis for PLGA and polylactic acid due 
to shorter reaction times and higher monomer conversion 
rates.14 The discovery and synthetic work on low molecular 
weight oligomeric forms of lactide and/or glycolide polymers 
were first carried out several decades ago.15 A method to 
synthesize high molecular weight forms of such polymers 
was first reported by Lowe.16 During the late 1960s and early 
1970s, a number of groups published their pioneering work 
on the utility of these polymers in the manufacture of sutures 
and fibers.15,16 Since then, these polymers have been used in a 
broad range of pharmaceutical and biomedical applications. 
Various polymeric devices, such as microspheres, micro-
capsules, nanoparticles, pellets, implants, and films have 
been fabricated using these polymers. They are also easy to 
formulate into various delivery systems for carrying a variety 
of active agents, such as vaccines, peptides, proteins, and 
micromolecules, some of which are now approved by the Food 
and Drug Administration for use in drug delivery.14–18
In order to improve the formulation of controlled drug 
delivery devices, an understanding of the physical, chemi-
cal, and biological properties of polymers is helpful. The 
polylactic acid polymer can exist in an optically active 
stereoregular form (L-polylactic acid) and in an optically 
inactive racemic form (D, L-polylactic acid). L-polylactic 
acid is semicrystalline in nature due to the high regularity of 
its polymer chain structure, while D, L-polylactic acid is an 
amorphous polymer because of irregularities in its polymer 
chain structure. Polyglycolide is highly crystalline because 
it lacks the methyl side groups of polylactic acid.15 PLGA 
copolymers prepared from L-polylactic acid and polygly-
colide are crystalline, while those from D, L-polylactic acid 
and polyglycolide are amorphous in nature. It has been found 
that PLGAs containing less than 70% glycolide are amor-
phous. The degree of crystallinity and the melting point of 
the polymers are directly related to their molecular weight. 
The mechanical strength, swelling behavior, capacity to 
undergo hydrolysis, and, subsequently, the biodegradation 
rate, are directly influenced by the crystallinity of the PLGA 
polymer, which depends on the type and molar ratio of the 
individual monomer components (lactide and glycolide) in 
the copolymer chain.15,19 Lactic acid is more hydrophobic than 
glycolic acid and, therefore, lactide-rich PLGA copolymers 
are less hydrophilic, absorb less water, and subsequently, 
degrade more slowly.20,21
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Figure 1 Chemical structure of polylactide-co-glycolide.
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The glass transition temperatures of PLGA copolymers 
are above the physiological temperature of 37°C, and hence 
they are normally glassy in nature, with sufficient strength to 
be formulated as a drug delivery system. The glass transition 
temperatureof a PLGA copolymer decreases with reducing 
molecular weight and lactide content.15
Mechanism of biodegradation  
of PLGA
A fundamental understanding of the in vivo phenomenon of 
PLGA biodegradation is important because this determines the 
rate and mechanism of the release of therapeutic agents. The 
therapeutic agent is either dispersed throughout the polymeric 
matrix or encapsulated in the hydrophobic nanoparticle core. 
The release of a therapeutic agent from nanoparticles has usu-
ally been shown to be biphasic, initially by diffusion through 
the polymer matrix and later bydiffusion of the therapeutic 
agent and degradation of the polymer matrix itself.22,23 PLGA 
copolymers are degraded in the body by hydrolytic cleavage of 
the ester linkage to lactic and glycolic acid (Figure 2). These 
monomers are easily metabolized in the body via the Krebs 
cycle and eliminated as carbon dioxide and water.15,24
The polymer degradation process both in vitro and in vivo 
is affected by several factors, including the method of prepa-
ration, the presence of low molecular weight compounds 
(monomers, oligomers, catalysts), size, shape and morphol-
ogy, the intrinsic properties of the polymer (molecular weight, 
chemical structure, hydrophobicity, crystallinity, and glass 
transition temperature),15 physicochemical parameters (pH, 
temperature, and ionic strength of the environment), site of 
implantation, and mechanism of hydrolysis. In general, the 
degradation time will be shorter for low molecular weight, 
more hydrophilic, and more amorphous polymers, and for 
copolymers with a higher glycolide content.
Although PLGA copolymers can undergo surface erosion in 
some conditions, bulk erosion is the main degradation pathway 
(Figure 3). This occurs by random scission of ester bonds in the 
polymer backbone occurring homogeneously throughout the 
device.18 A three-phase mechanism for PLGA   biodegradation 
has been proposed. Initially, a significant decrease in the 
  molecular weight of the polymer is observed, with no appre-
ciable weight loss and no soluble monomer products formed 
after random chain scission. This phase is followed by a decrease 
in molecular weight, with rapid loss of mass and formation of 
soluble monomeric and oligomeric products. Finally, soluble 
monomer products are formed from soluble oligomeric frag-
ments, resulting in complete polymer degradation.15
Methods for preparation  
of PLGA nanoparticles
Several methods for polymeric nanoparticle production 
have been developed by researchers. These methods gener-
ally include two main steps. The first step is to prepare an 
emulsified system, and this is common to all the methods 
used. The nanoparticles are formed during the second step, 
which varies according to the method used. In general, the 
principle of this second step gives its name to the method. 
Some methods do not require the preparation of an emulsion 
prior to obtaining the nanoparticles, and are based on spon-
taneous precipitation of a polymer or through self assembly 
of macromolecules.25 The commonly used methods for 
preparation of PLGA nanoparticles are briefly described.
Emulsification solvent evaporation
Emulsification solvent evaporation is one of the most fre-
quently used methods. The polymer and the drug are first 
dissolved in a water-immiscible volatile solvent, such as 
dichloromethane or chloroform, which is then emulsified in an 
aqueous solution containing a stabilizer. The emulsification is 
brought about by subsequent exposure to a high-energy shear-
ing source, such as an ultrasonic device or homogenizer. The 
organic phase is evaporated under reduced pressure or vac-
uum, resulting in a fine aqueous dispersion of   nanoparticles. 
The nanoparticles are collected by ultracentrifugation and 
washed with distilled water to remove stabilizer residues or 
any free drug, and then lyophilized for storage.1,26,27
The emulsion evaporation method can be used for 
the preparation of particles with sizes varying from a few 
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  nanometers to micrometers by controlling the stirring rates 
and conditions, and shows high efficiency forthe incorpora-
tion of lipophilic drugs.28–30 To entrap hydrophilic drugs, the 
double-emulsion technique is employed, which involves the 
addition of aqueous drug solution to organic polymer solution 
under vigorous stirring to form a water-in-oil emulsion. This 
water-in-oil emulsion is added into a second aqueous phase 
containing a stabilizer with stirring to form the water-in-oil-
in-water emulsion. The emulsion is then subjected to solvent 
removal by evaporation.31,32
Emulsification solvent diffusion
This method is also known as emulsification and solvent 
displacement. The solvent used to prepare the emulsion 
needs to be partly soluble in water.33 The polymeric solu-
tion is added to an aqueous solution, containing stabilizer, 
under vigorous   stirring.18 Once the oil-in-water emulsion is 
obtained, it is diluted with a large quantity of pure water. As 
a result of this dilution, additional organic solvent from the 
organic phase contained in the dispersed droplets can diffuse 
out of the droplets, leading to precipitation of the polymer. 
Suitable solvents include benzyl alcohol, propylene carbon-
ate, ethyl acetate, isopropyl acetate, methyl acetate, methyl 
ethyl ketone, benzyl alcohol, butyl lactate, and isovaleric 
acid. This method has been used for PLGA nanoparticle 
preparation in many studies.34–37 It should be noted that the 
solvent evaporation process is similar to this method, in the 
sense that the solvent must first diffuse out into the external 
aqueous dispersion medium before it can be removed from 
the system by evaporation.25
Emulsification reverse salting-out
The emulsification reverse salting-out technique involves the 
addition of polymer and drug solution to a water-miscible solvent, 
such as acetone, and to an aqueous solution containing the 
salting-out agent, such as magnesium chloride, calcium 
chloride, and a colloidal stabilizer, such as polyvinyl pyr-
rolidone, under vigorous mechanical stirring. When this 
oil-in-water emulsion is diluted with a sufficient volume of 
water, it induces the formation of nanoparticles by enhancing 
the diffusion of acetone into the aqueous phase. The dilution 
produces a sudden decrease in the salt concentration in the 
continuous phase of the emulsion, inducing the polymer sol-
vent to migrate out of the emulsion droplets. The remaining 
solvent and salting-out agent are eliminated by cross-flow 
filtration.1,38,39 Although the emulsification-diffusion method 
is a modification of the salting-out procedure, it has the 
advantage of avoiding the use of salts and thus eliminates 
the need for intensive purification steps.18
Nanoprecipitation
The nanoprecipitation method is a one-step procedure, also 
known as the solvent displacement method.40 It is usually 
employed to incorporate lipophilic drugs into the carri-
ers based on the interfacial deposition of a polymer.41,42 
  Nanoprecipitation is performed using systems containing 
three basic ingredients, ie, the polymer, the polymer solvent, 
and the nonsolvent of the polymer. The solvent should be 
organic, miscible in water, and easily removed by   evaporation. 
For this reason, acetone is the most frequently used solvent 
with this method.43 Sometimes it exists as a binary blend of 
solvents, as acetone with a small amount of water, or as a blend 
of ethanol and acetone. Polymer, drug, and lipophilic surfac-
tant (eg, phospholipids) are dissolved in a semipolar water-
miscible solvent, such as acetone or ethanol. The solution is 
then poured or injected into an aqueous solution containing 
stabilizer under magnetic   stirring. Nanoparticles are formed 
immediately by rapid solvent diffusion. The solvent is then 
removed from the suspension under reduced pressure.15,18
Nanoparticle characterization 
techniques
Characterization of nanoparticles is essential for a thorough 
understanding of their properties before developing them 
further for pharmaceutical application. Nanoparticle size 
is critical, not only in determining the release profile and 
degradation behavior, but also in determining the efficacy 
of the therapeutic agent in terms of tissue penetration and 
cellular uptake.44 The molecular weight of the polymer influ-
ences the nanoparticle size, encapsulation efficiency, and 
degradation rate of the polymer, hence affecting the release 
rate of the therapeutic agent,45 as shown by Konan et al who 
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Figure 3 Degradation mechanisms of biodegradable polymeric nanoparticles: A) 
bulk erosion, B) surface erosion.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  demonstrated that the molecular weight of PLGA impacts 
the final mean nanosphere size. In general, higher molecu-
lar weights form nanoparticles of larger size. Change in 
  nanoparticle size has been evaluated according to changes 
in PLGA composition and molecular weight (12–48 kDa 
for 50:50 PLGA and 12–98 kDa for 75:25 PLGA).39 For 
the nanospheres with 50:50 PLGA, mean size ranged 
from 102 ± 4 nm to 154 ± 17 nm for 12 kDa and 48 kDa, 
  respectively. For the 75:25 PLGA, nanoparticle mean size 
ranged from 132 ± 3 nm to 152 ± 25 nm for 12 kDa and 
98 kDa, respectively.
In another study, Mittal et al prepared estradiol-loaded 
PLGA nanoparticles with different molecular weights 
(14.5, 45, 85, 135, and 213 kDa) by the emulsion-diffusion-
  evaporation method, and showed that entrapment efficiency 
did not follow a regular pattern. First, it decreased from 
51.3% to 34.5% as molecular weight was increased from 
about 14.5 kDa to 85 kDa, and, thereafter, a significant 
increase (P , 0.05) to 67.8% was observed as molecular 
weight was increased to 213 kDa. Entrapment efficiency of 
particles using the oil-in-water method depends mainly on the 
drug partition coefficient in the internal and external phases. 
It is possible that an increase in viscosity on increasing the 
molecular weight might have decreased the diffusion rate 
of the solvent into the external aqueous phase. The polymer 
precipitated slowly because of a slow rate of solvent removal, 
giving the drug molecules more time to come into the aqueous 
phase, resulting in low entrapment efficiency. However, an 
increase inentrapment efficiency was observed for particles 
with molecular weights of 137 kDa and 213 kDa, which 
could be due to strong hydrophobic interaction between the 
molecular chains of the polymer and the drug.46
An increase in molecular weight from 14.5 kDa to 
213 kDa was associated with a significant decrease in the 
rate of release of estradiol. Molecular weight is indicative of 
polymer chain length, and the higher the molecular weight, 
the longer the chain length. Furthermore, chain length reflects 
the hydrophilicity or lipophilicity of the polymer. An increase 
in chain length increases the lipophilicity and decreases the 
degradation rate of the polymer. Therefore, by varying the 
molecular weight, the degradation rate of the polymer and 
release kinetics of the drug can be controlled.15,46
The physical state of both the drug and the polymer need 
to be determined because this will have an influence on the 
in vitro and in vivo drug release characteristics. The zeta 
potential can influence particle stability and   mucoadhesion, 
as well as intracellular trafficking of nanoparticles as a 
  function of pH. Hydrophobicity determines the distribution 
of nanoparticles in the body after administration. Hydrophilic 
particles tend to remain in the blood for a longer time.18,27,47 
There are many sensitive techniques for characterizing nano-
particles, depending upon the parameter being investigated. 
These techniques are summarized in Table 1.
PLGA nanoparticles for drug 
delivery to tumors
Cancer is a worldwide public health problem, and tens of 
millions of people presently suffer from this deadly disease.82 
Cancer research involves intensive scientific efforts to iden-
tify the causes of cancer and to develop specific strategies for 
its prevention, diagnosis, treatment, and cure. Despite consid-
erable progress in its early diagnosis, but progress concerning 
its treatment has been less so. In current anticancer therapy, 
drugs are administered via the intravenous and/or oral route 
using conventional formulations, including injections, 
  tablets, and capsules. Controlled and targeted delivery of an 
anticancer agent at the site of action is necessary to maximize 
the killing effect during the tumor growth phase and to avoid 
drug exposure to healthy adjacent cells, thereby reducing 
drug toxicity. It is also desirable to maintain a steady rate of 
infusion of the drug into the tumor to maximize exposure to 
dividing cells, resulting in tumor regression.83
Development of novel systems for delivery of anti-
cancer drugs is a recent topic of research. Abraxane®, an 
albumin-based formulation of paclitaxel from Abraxis 
Oncology, Nanoxel®, a nanoliposome containing paclitaxel 
from   DaburPharma, and Doxil®, a nanoliposome   containing 
  doxorubicin from Ortho Biotech, are now well-known 
  commercial products.82,84–89
Table  1  Techniques  for  polylactide-co-glycolide  nanoparticle 
characterization
Particle size, size  
distribution, morphology
Dynamic light scattering or  
photon correlation spectroscopy41,48,49
Scanning electron microscopy28,50,51
Transmission electron microscopy52–54
Atomic force microscopy55–57
Molecular weight Size exclusion chromatography58–60
Surface chemistry 
analysis
X-ray photoelectron spectroscopy28,61,62
Fourier transform infrared spectroscopy54,63,64
Nuclear magnetic resonance spectroscopy64–66
Surface charge Zetasizer56,67,68
Crystallinity X-ray diffraction37,69,70
Differential scanning calorimetry71–73
Hydrophobicity,  
hydrophilicity
water contact angle measurements65,74,75
Hydrophobic interaction chromatography76–78
Drug entrapment 
efficiency, drug 
release studies
Size exclusion chromatography79,80
High-performance liquid 
chromatography59,67,81International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Nanoparticle-based drug delivery systems have many 
advantages for anticancer drug delivery, including an ability 
to pass through the smallest capillary vessels, because of their 
very small volume, and being able to avoid rapid clearance 
by phagocytes, so that their presence in the blood stream is 
greatly prolonged.90 Nanoparticles can also penetrate cells 
and gaps in tissue to arrive at target organs, including the 
liver, spleen, lung, spinal cord, and lymph. They may have 
controlled-release properties due to their biodegradability, 
pH, ions, and/or temperature sensitivity. All these properties 
can improve the utility of anticancer drugs and reduce their 
toxic side effects.
PLGA nanoparticles linked to targeting ligands are used 
to target malignant tumors with high affinity. PLGA nanopar-
ticles also have large surface areas and functional groups for 
conjugating to multiple diagnostic (eg, optical, radioisotopic, 
or magnetic) agents.91 Nanoparticle carriers have high stabil-
ity in biological fluids, and are more able to avoid enzymatic 
metabolism than other colloidal carriers, such as liposomes 
or lipid vesicles.92 Most anticancer drugs that have been 
investigated in PLGA nanoparticle preparations are discussed 
below. They are also summarized in Table 2.
Paclitaxel
Many anticancer drugs can be used clinically to treat various 
cancers, but have limited efficacy due to poor cell   penetration. 
For example, paclitaxel, a mitotic inhibitor, has had limited 
clinical application because of its low therapeutic index, 
and its low solubility in water and many other pharmaceu-
tical solvents acceptable for intravascular administration. 
  Incorporation of paclitaxel into PLGA nanoparticles strongly 
enhances its antitumoral efficacy compared with the free 
drug (Taxol®), with this effect being more relevant after more 
prolonged incubation with cells. Based on these results, it 
can be concluded that the formulations developed so far 
may be considered promising systems for in vivo paclitaxel 
delivery.49
In an animal model, Van Vlerken et al encapsulated pacli-
taxel and the apoptotic signaling molecule, C6-ceramide, 
into a PLGA/poly (β-amino ester)-blended polymer. When 
this nanoparticle formulation was administered intrave-
nously to MCF7 and MCF7TR-tumor-bearing mice, higher 
concentrations of paclitaxel were found in the blood due to 
a longer retention time and enhanced tumoral accumulation 
compared with the free drug. In addition, the PLGA/poly 
(β-amino ester)-blended nanoparticles were effective in 
enhancing the residence time of both drugs at the tumor site 
by reducing systemic clearance.93
In another study, Feng et al developed paclitaxel-loaded 
nanoparticles to achieve better therapeutic effects with 
minimum side effects. In this investigation, phospholipids, 
cholesterol, and vitamins were used to replace traditional 
chemical emulsifiers to achieve high encapsulation efficacy 
and the desired drug release rate.94
The methodology and experimental parameters used for 
nanoparticle preparation can impact the physicochemical 
properties of the resulting formulations. Danhier et al have 
reported significantly higher encapsulation efficacies for 
paclitaxel loaded into PLGA nanoparticles using the nano-
precipitation method (70%) compared with the emulsion/
solvent evaporation technique (40%).59 Elsewhere, it was 
shown that an increase in the oil-to-water phase ratio49 and the 
polymer concentration of the organic phase95 could enhance 
the entrapment efficacy of paclitaxel within polyester-based 
nanoparticles produced by the nanoprecipitation technique. 
Alternatively, the organic solvent can be dialyzed against 
water to obtain polyester-based nanoparticles incorporating 
paclitaxel.96–99
Mu and Feng used α-tocopheryl polyethylene glycol 
l000 succinate (vitamin E TPGS) as well as a matrix material 
with other biodegradable polymers for the fabrication of a 
nanoparticle formulation of paclitaxel. They concluded that 
vitamin E TPGS was advantageous either as an emulsifier or 
as matrix material blended with PLGA for the manufacture of 
nanoparticles enabling controlled release of paclitaxel.28
Surfactants and stabilizers are used to increase the physi-
cal stability of nanoparticles. Reports of the positive surface 
charge of a quaternary ammonium salt, didodecyl dimethyl 
ammonium bromide (DMAB), provided the incentive to 
aid the delivery of paclitaxel, because it was expected to 
ensure better interaction with the negatively charged cell 
membrane. This could result in increased retention time at 
the cell surface, thus increasing particle uptake.100 In another 
study, the safety and utility of DMAB for stabilizing PLGA 
nanoparticles was studied. The preliminary data from this 
study provide proof-of-concept of improved efficacy and 
safety of oral paclitaxel chemotherapy.101
Docetaxel
PLGA nanoparticles containing docetaxel with the desired 
size and drug-loading characteristics suitable for intra-
venous administration can be prepared without using 
Tween®80. Esmaeili et al showed that the cellular   cytotoxicity 
of the   nanoparticles was higher than for the free drug. 
  Docetaxel-loaded nanoparticles reached good plasma lev-
els in vivo in comparison with a conventional formulation International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Table 2 Summary of polylactide-co-glycolide nanoparticles
Polymer for  
nanoparticle  
preparation
Drug Size (nm) Zeta potential  
(mV)
EE 
(% w/w)
Loading 
(% w/w )
Cell line Reference
PLGA Paclitaxel ,200 (−23)–(−31) 70–90 1 NCI-H69 (SCLC) 49, 81
PeGylated PLGA Paclitaxel 112 −0.556 ± 5.7 70 HeLa 59
PLGA Paclitaxel 300 −20 75 4 C6 glioma 97
PLGA Paclitaxel 270–500 50 2.4 28
PLGA Docetaxel 172 −12.2 68 0.34 T47D, MCF7, SKOv3, A549 102
PLGA Docetaxel 150 −6 16.8 0.5 73
PLGA-mPeG Cisplatin 150–160 2 HT29 cells 103
PLGA-mPeG Cisplatin 130–160 (−5.7)–(−9.3) 1.99–2.96 LNCaP 104
PLGA Doxorubicin 230 −45 80 5 MDA-MB-231 42
PLGA ICG and DOX 170 −9.9 ± 0.4 depending 
on PLGA and PvA 
concentration
44 (ICG)  
74 (DOX)
0.015 (ICG)  
0.022 (DOX)
107
PLGA Curcumin 45 90 LNCaP, PC3, DU-145 109
PLGA Curcumin 76 0.06 89.5 A2780CP, MDA-MB-231 110
PLGA Docetaxel 217 −23.35 ± 1.17 87.99 11.11 MCF-7 TAX30 114
PLGA vincristine 
verapamil
98 −0.75 ± 0.12 68 (vCR)  
80 (vRP)
MCF-7/ADR 115
PLGA Hypericin 200–300 −7.9 15.4 0.2 NuTu-19 116
PLGA Zinc (II)  
Phthalocyanine
200 80 P388-D1 152
PLGA Paclitaxel 182 −3.45 ± 0.58 for 
Pluronic®(P85)
C6 rat glioma 153
PLGA-d-a-TPGS Docetaxel 250 −18.03 99.31 10 HeLa 122
DMAB-modified 
PLGA-TPGS
Docetaxel 220 32.2 96 9.62 MCF-7, Caco-2 154
PLGA Paclitaxel 240 −35.6 66.21 5 HT-29 155
PLGA Paclitaxel 200–300 34–62 glioma C6 cells 156
PLGA ethylene 
oxide fumarate
Paclitaxel 190 57–70 3 HCT116 157
Abbreviations: PLGA, polylactide-co-glycolide; DMAB, didodecyl dimethyl ammonium bromide; ICG, indocyanine green; DOX, doxorubicin; SCLC, small cell lung cancer; 
PVA, polyvinyl alcohol; VCR, Vincristine; VRP, Verapamil; EE, entrapment efficiency.
of docetaxel (Taxotere®).102 The nanoprecipitation process 
has been applied for the formation of docetaxel-loaded 
nanoparticles.66,73 Cheng et al showed that limiting drug-
loading to 1% (w/w) minimized particle aggregation and 
yielded docetaxel-loaded PLGA nanoparticles with narrower 
size distributions.66
Cisplatin
Mattheolabakis et al prepared cisplatin nanoparticles with 
an average size of 150–160 nm and an approximately 2% 
w/w cisplatin content using a modified emulsification and 
solvent evaporation method. The cisplatin-loaded PLGA-
monomethoxy (m)PEG nanoparticles appeared to be 
effective in delaying tumor growth in HT29 tumor-bearing 
mice with severe combined immune deficiency. The group 
of mice treated with cisplatin-loaded nanoparticles had a 
higher survival rate compared with the free cisplatin group.103 
Cisplatin-loaded PLGA-mPEG nanoparticles also resulted in 
prolonged cisplatin residence time in the systemic circulation 
when used in mice with prostate cancer.104
Doxorubicin
Betancourt et al formulated nanoparticles by nanoprecipita-
tion of acid-ended PLGA to control the release of doxoru-
bicin in a pH-dependent manner and deliver high loads of 
active drug to an MDA-MB-231 breast cancer cell line. The 
  pH-dependent release behavior could be a result of acceler-
ated degradation of the polymer and decreasing ionic interac-
tion between the drug and the polymer at an acidic pH.42
Another approach to improve the efficacy and   selectivity 
of cancer treatment is the application of hyperthermia in 
combination with traditional cancer therapeutics, such as 
radiation therapy and chemotherapy.105,106 Hyperthermia 
makes some cancer cells more sensitive to radiation and 
can also enhance the effect of certain anticancer drugs,106 
thus allowing the use of decreased chemotherapy doses. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Indocyanine green is an optical tracer that can generate heat 
by absorbing near-infrared light. The significance of the 
  Manchanda et al study is the synthesis of multifunctional 
PLGA nanoparticles and the incorporation of drugs with 
different physical properties (indocyanine green being 
amphiphilic and doxorubicin being hydrophobic). These 
indocyanine green-doxorubicin nanoparticles have potential 
applications as drug delivery systems for combined chemo-
therapy and localized hyperthermia.107
Curcumin
Curcumin has been used in traditional medicine for many 
centuries in India and China.108 It is chemically diferuloyl-
methane, a yellow polyphenol extracted from the rhizomes 
of turmeric (Curcuma longa). The only factor that limits the 
use of free curcumin for cancer therapy is its poor solubility 
in water, which in turn limits its systemic bioavailability when 
administered orally. Mukerjee and Vishwanatha formulated 
curcumin-loaded PLGA nanoparticles, and suggested that a 
nanoparticle-based formulation of curcumin has high poten-
tial as adjuvant therapy in prostate cancer.109
Another study demonstrated that curcumin encapsula-
tion in PLGA nanoparticles employing a nanoprecipitation 
approach in the presence of polyvinyl alcohol and poly 
L-lysine stabilizers not only produced a very stable nanofor-
mulation but also enhanced cellular drug uptake and reten-
tion, as well as sustained release of curcumin. The optimized 
nanoparticle formulation has shown a greater inhibitory 
effect on the growth of metastatic cancer (A2780CP and 
MDA-MB-231) cells than free curcumin.110
Multidrug resistance
A major barrier to successful cancer treatment is multidrug 
resistance. It has been reported that most patients, even those 
who are initially responsive, acquire a multidrug-resistant 
phenotype, and some patients show multidrug-resistance 
even at their first treatment. In metastatic breast cancer, the 
development of a multidrug-resistant phenotype is primarily 
responsible for insensitivity to a new drug.111 Therefore, resis-
tance to chemotherapeutic agents is the major challenge in the 
treatment of breast cancer. It has been shown that nanoparticles 
can reduce the multidrug-resistance characterizing many anti-
cancer drugs via a drug internalization mechanism mediated by 
P-glycoprotein, thereby reducing its efflux from cells.112,113
Yan et al showed that the cytotoxicity of a PLGA-
  poloxamer188 nanoparticle blend containing docetaxel 
against MCF-7 TAX30 cells was higher than that of the free 
drug, indicating that poloxamer188 could enhance the ability 
of PLGA nanoparticles to overcome multidrug resistance. 
A docetaxel-loaded PLGA-poloxamer188 nanoparticle formu-
lation has been developed to overcome multidrug resistance 
in a docetaxel-resistant human breast cancer cell line (MCF-7 
TAX30).114
Multidrug resistance may be treated using a combina-
tion of entrapped cytotoxic drugs and chemosensitizers. 
To optimize the effectiveness of this approach, Song et al 
prepared PLGA nanoparticle formulations capable of 
delivering vincristine (a cytotoxic drug) and verapamil 
(a chemosensitizer), or a combination of these agents by 
combining the oil-in-water emulsion solvent evaporation and 
salting-out methods. PLGA nanoparticles showed moderate 
multidrug-resistance reversal in MCF-7/ADR cells resistant 
to vincristine. Coencapsulation of an anticancer drug and 
chemosensitizer may cause lower drug toxicity and fewer 
drug–drug interactions. Therefore, PLGA nanoparticles 
simultaneously loaded with an anticancer drug and a chemo-
sensitizer may potentially be a very promising formulation 
for treatment of drug-resistant cancers in vivo.115
Photodynamic therapy
Photodynamic therapy combines a photosensitizing agent 
with a specific type of light to kill cancer cells. This technique 
is minimally invasive, with great potential in both malignant 
and premalignant conditions. Photodynamic therapy requires 
the presence of a photosensitizing agent, oxygen, and light 
of a specific wavelength matching the absorption charac-
teristics of the photosensitizer agent. Administration of the 
photosensitizer is followed by illumination of the tumor with 
visible light in a wavelength range matching the absorption 
spectrum of the photosensitizer agent.
Hypericin, a natural photosensitizer extracted from 
Hypericum perforatum, is a potential tool for the detection 
and treatment of ovarian and other cancers. Due to its hydro-
phobicity, systemic administration of hypericin is problematic. 
A  photodynamic  approach  has  been  suggested  by 
  Zeisser-Labou et al to improve the diagnosis and treatment 
of ovarian cancer.116 This group used polymeric nanoparticles 
of polylactic acid or PLGA as a drug delivery system, and 
compared the in vitro photoactivity of the nanoparticles and 
that of the free drug using the NuTu-19 ovarian cancer cell 
model derived from Fischer 344 rats. Their studies showed that 
hypericin-loaded nanoparticles exhibited higher photoactivity 
than did the free drug, and increasing light dose and cell 
incubation time enhanced their activity.
Ricci-Junior and Marchetti have prepared, characterized, 
and assayed the photocytotoxicity of PLGA nanoparticles International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  containing zinc (II) phthalocyanine for use in photodynamic 
therapy. These nanoparticles maintained their photophysical 
behavior after the encapsulation process.51
Surface modification of PLGA 
nanoparticles
Polymeric nanoparticles have been characterized by their mor-
phology and polymer composition. The drug molecule is either 
conjugated to the surface of the nanoparticles or entrapped and 
protected inside the core. The unique sizes of these nanopar-
ticles are amenable to surface functionalization or modification 
to achieve any desired characteristics. This has been achieved 
by various methods to increase drug retention time in blood, to 
reduce nonspecific distribution, and to target tissues or specific 
cell surface antigens with targeting ligands, such as peptides, 
aptamers, antibodies, and small molecules.117
Opson in proteins present in the bloodstream quickly 
bind to conventional nonstealth nanoparticles, allowing mac-
rophages of the molecular phagocytic system to recognize 
and remove these drug delivery devices before they can exert 
their therapeutic effects.118 Opsonization of injected particles 
by antibodies in the circulation, attachment of opsonized 
particles to macrophages, and subsequent internalization by 
phagocytosis are important steps in the clearance of particles 
by the molecular phagocytic system.
Different materials are used for the preparation of nano-
particles, leading to distinct surface properties. Surface 
modification of nanoparticles is important for escaping the 
body’s natural defense systems when transporting drugs 
to the bloodstream.78 Unless nanoparticles are modeled to 
escape recognition by the molecular phagocytic system, 
they will be eliminated from the body. A long circulation 
time increases the probability that the nanoparticles will 
reach their target. Nanostructures smaller than 100 nm with 
a hydrophilic surface have the greatest ability to evade the 
molecular phagocytic system.30
To increase circulation time, the particles can be coated 
with molecules that provide a hydrophilic protective layer, 
such as PEG, polyvinylpyrrolidone, human serum albumin, 
poloxamers, polysorbate 80, polysorbate 20, vitamin E 
TPGS, polysaccharides (eg, dextran) and different types of 
copolymers.119 Here we discuss three of the more impor-
tant materials used for surface modification of PLGA 
nanoparticles.
Polyethylene glycol
Adsorption or grafting of PEG to the surface of nanoparticles 
is the preferred method for shielding nanoparticles from 
the molecular phagocytic system.59,103,104 Addition of PEG 
or PEG-containing copolymers to the nanoparticle surface 
results in an increase of half-life in the blood circulation by 
several orders of magnitude. This method creates a protec-
tive hydrophilic layer around the nanoparticles that is able 
to repel the adsorption of proteins via steric repulsion forces, 
thereby blocking and delaying the first step in the opsoniza-
tion process.118
PEG is a hydrophilic nonionic polymer that has been shown 
to have excellent biocompatibility. PEG coating on the surface 
of polymers reduces interaction between the nanoparticles and 
digestive enzymes, and increases uptake of the encapsulated 
drug in the bloodstream and lymphatic tissue.120
PLGA nanoparticles have been surface-modified with 
PEG in an attempt to protect them from the reticuloendothe-
lial system.59,103,104 Avgoustakis et al considered the feasibility 
of using long circulating PLGA-mPEG nanoparticles as car-
riers for passive targeting of cisplatin to tumors. They showed 
that intravenous administration of PLGA-mPEG nanopar-
ticles loaded with cisplatin in mice resulted in a prolonged 
residence time of cisplatin in the systemic circulation.65
vitamin e TPGS
TPGS is a widely used form of vitamin E that has been used 
as a solubilizer, an emulsifier, and a vehicle in drug delivery 
formulations. TPGS has been used as an emulsifier for pro-
ducing nanoparticles containing hydrophobic drugs and for 
improving encapsulation efficiency, drug loading, and the 
release profile of nanoparticles.81 Surface modification by 
TPGS increases adhesion of the nanoparticles to the tumor 
cell surface.78,121 TPGS has also been blended with PLGA 
for the preparation of nanoparticles.28 TPGS increases adhe-
sion of PLGA nanoparticles to cells and the hemodynamic 
properties of the nanoparticles.
Ma et al synthesized PLGA-TPGS copolymers as nano-
particle carriers for small molecular weight anticancer drugs, 
using docetaxel as a model drug. In vitro cellular uptake 
of these nanoparticles was investigated by confocal laser 
scanning microscopy, which demonstrated that fluorescent 
PLGA-TPGS nanoparticles could be internalized by HeLa, 
a human cervical carcinoma cell line. Random PLGA-TPGS 
copolymers could act as a novel and potential biocompatible 
polymeric matrix material applicable to nanoparticle-based 
drug delivery systems for cancer chemotherapy.122
Pluronic®
Pluronic block copolymers consist of ethylene oxide and 
propylene oxide blocks arranged in a basic A-B-A structure, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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ie, ethylene oxide-propylene oxide-ethylene oxide. The 
incorporation of drugs into the core of the micelles formed 
by Pluronic results in increased solubility, metabolic stability, 
and a longer circulation time for the drug.123
Kabanov et al demonstrated that Pluronics P85, F68, and 
L61 reduced the respiration rate of both drug-sensitive cells and 
the molecular phagocytic system, resulted in hypersensitivity 
to chemotherapy. Cells often achieve their drug resistance via 
the efflux of drugs through energy-dependent transporters, so 
reduction in respiration impairs this mechanism.123
Shah et al formulated paclitaxel-PLGA   nanoparticles 
surface-modified with Pluronic P85 for inhibition of 
P-glycoprotein. This study demonstrated the feasibility 
of targeting nanoparticles to specific cancer tumor cells, 
cell internalization, and successful overcoming of the 
P-glycoprotein-mediated paclitaxel efflux mechanism, and 
demonstrated a significant increase in uptake of Pluronic 
P85-coated nanoparticles.124
PLGA nanoparticle targeting 
strategies
In the process of killing cancer cells, chemotherapeutic 
agents also damage healthy tissues, leading to systemic 
toxicity and adverse side effects. Thus, an important step 
in improving treatment regimes is achieving more effective 
targeting of anticancer drugs to tumor tissues. Therefore, the 
need to develop novel cancer therapies and drug delivery 
strategies specifically targeted to tumor cells continues to 
be a major focus for   scientists. Nanoparticle systems offer 
major improvements in therapeutics through site specificity, 
an ability to evade multidrug resistance, and efficient delivery 
of anticancer agents.125
Ideally, drug delivery systems should improve the sta-
bility, absorption, and therapeutic action of the drug within 
the target tissue and permit controlled release of the drug. 
Targeting cancer cells using nanoparticles loaded with 
  anticancer agents is a promising strategy that could overcome 
these challenges. Drug targeting can be achieved by taking 
advantage of the distinct pathophysiological features of tumor 
tissue (ie, passive targeting) or by actively targeting the drug 
carrier using target-specific ligands (ie, active targeting).126,127
Passive targeting
Passive targeting exploits the anatomical differences between 
normal tissue and tumor tissue to deliver drugs to the 
desired site. The vasculature in tumor tissues is very   different 
from that in normal tissues. It is more heterogeneous in 
  distribution, larger in size, has higher vascular density, and is 
more permeable and leaky, with gap sizes of 100 nm to 2 µm 
depending on the tumor type, unlike the tight endothelium 
of normal blood vessels. In addition, extensive production 
of vascular mediators, including bradykinins, nitric oxide, 
vascular endothelial growth factor, and prostaglandins, facili-
tates extravasation. This, coupled with impaired lymphatic 
drainage of macromolecules in solid tumors, allows enhanced 
accumulation and retention of high molecular weight drugs 
in solid tumors. This is popularly known as the “enhanced 
permeation and retention effect”, that allows extravasation 
of circulating polymeric nanoparticles within the tumor 
interstitium and also increases concentrations of the chemo-
therapeutic agent within the tumor tissue (Figure 4).125–127 It 
should be mentioned that nanoparticles within the size range 
of 60–400 nm are effective for this type of targeting.128,129
These are three in vivo studies based on the permeation 
and retention effect. Bhardwaj et al formulated PLGA-
  paclitaxel nanoparticles stabilized with DMAB and admin-
istered orally to female Sprague Dawley rats.101   Paclitaxel 
nanoparticles administered orally were as effective as 
paclitaxel given intravenously with Cremophor® EL at a 
50% reduced dose, and was significantly better than oral 
paclitaxel in the Cremophor EL group. This in vivo proof-
of-concept study provides encouraging evidence of the value 
of nanoparticulate anticancer formulations, and highlights 
the anticancer efficacy of paclitaxel when incorporated into 
nanoparticles. The nanoparticle formulation was as effec-
tive as the drug used alone, but at half the dose. The average 
tumor weight measured after paclitaxel orally administered 
in Cremophor was roughly three-fold higher than after the 
nanoparticulate formulation.101
Danhier et al formulated Cremophor EL-free paclitaxel-
loaded PEGylated PLGA-based nanoparticles by a nanopre-
cipitation method. In vivo tumor growth inhibition by the 
paclitaxel-loaded nanoparticles was then investigated in trans-
plantable liver tumor-bearing mice. Paclitaxel was shown to 
reach the tumor site via the enhanced permeation and retention 
effect and maintain an effective therapeutic concentration.59
In another study, Mattheolabakis et al investigated toler-
ance of BALB/c mice to different doses of blank and cisplatin-
loaded PLGA-mPEG nanoparticles, and the in vivo anticancer 
activity of cisplatin-loaded PLGA-mPEG nanoparticles 
in mice with severe combined immune deficiency bearing 
HT29 colon adenocarcinoma. By in vivo antitumor activity 
assay, the PLGA-mPEG-cisplatin nanoparticles appeared to 
reduce tumor growth in mice with severe combined immune 
deficiency and HT29 xenografts, and these mice had higher 
survival rates than those treated with free cisplatin.103International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Active targeting
Active targeting involves the use of peripherally attached tar-
geting moieties for enhanced delivery of nanoparticle systems 
(Figure 5). Active targeting to the tumor can be achieved by 
molecular recognition of cancer cells either via ligand–receptor 
or antigen–antibody interactions, or by targeting through 
aptamers, that allow preferential accumulation of the drug in 
tumor tissue, within individual cancer cells or specific mol-
ecules in cancer cells. Long circulation times will allow for 
effective transport of the nanoparticles to the tumor site through 
the enhanced permeation and retention effect, and the target-
ing molecule can increase endocytosis of the   nanoparticles. 
The success of drug targeting depends on the selection of the 
targeting agent, which should be abundant, have high affin-
ity and specificity of binding to cell surface receptors, and 
should be well-suited to chemical modification by   conjugation. 
The   receptors and their surface-bound antigens may be 
expressed only in diseased cells or may exhibit a differentially 
higher expression in diseased cells as compared with normal 
cells. Thus, the tumor endothelium provides many targets for 
cancer therapy (Figure 6).127,130 Here we discuss the three main 
categories of targeting moieties used for PLGA nanoparticles. 
These targeted nanoparticles are also shown in Table 3.
Ligand–receptor interaction
The lectin–carbohydrate interaction is highly specific, and can 
be exploited for the development of nanoparticles containing 
carbohydrate moieties that are directed to certain lectins, or 
vice versa. Several lectins have been found to possess antican-
cer properties, and are used as therapeutic agents, preferentially 
binding to cancer cell membranes or their receptors, causing 
cytotoxicity, apoptosis, and inhibition of tumor growth.125
Non-targeted PLGA NP
Tumor cell
Normal cell
Endothelial cell
Extravasation
Extravasation
Figure 4 enhanced permeability and retention effect. Passive tissue targeting is achieved by extravasation of nanoparticles through increased permeability of the tumor 
vasculature and ineffective lymphatic drainage.
Abbreviations: PLGA, polylactide-co-glycolide; NP, nanoparticles.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Mo and Lym developed novel lectin-conjugated isopro-
pyl myristate-incorporating PLGA nanoparticles for local 
delivery of paclitaxel to the lungs. These nanoparticles had 
superior in vitro cytotoxicity against A549 and H1299 cells 
as compared with paclitaxel-loaded nanoparticles without 
Targeting
moiety
Surface
layer
Chemotherapeutic drug
(encapsulated in the core)
Figure 5 Targeted polylactide-co-glycolide nanoparticle carrying the chemotherapeutic 
drug.
Targeted 
PLGA NP
Receptors
Recycling
endosome
Late endosome
E
n
d
o
s
o
m
e
Figure 6 Internalization of targeted polylactide-co-glycolide nanoparticles via receptor-mediated endocytosis. Since specific receptors are overexpressed on tumor cells, the 
nanoparticles are selectively uptaken by the tumor cells via receptor–ligand interaction.
Abbreviations: PLGA, polylactide-co-glycolide; NP, nanoparticles.
isopropyl myristate or wheat germ agglutinin, or paclitaxel-
loaded nanoparticles with only isopropyl myristate or wheat 
germ agglutinin. Thus, their studies showed that these nano-
particles exhibited a stronger cytotoxic effect because of more 
efficient cellular uptake via wheat germ agglutinin receptor-
mediated endocytosis and isopropyl myristate-facilitated 
release of paclitaxel from the nanoparticles.52
There is broad interest in the development of nanopar-
ticles carrying carbohydrates, such as sialic acids, on their 
surface. Macromolecular compounds containing these 
carbohydrates show an antirecognition effect, exert an anti-
viral effect, and are also able to be recognized by the cell 
surface of some cancer cell types.131 Bondioli et al used two 
  different approaches to obtain polymeric PLGA nanoparticles 
surface-decorated with sialic acid N-acetylneuraminic acid 
(Neu5Ac). The first strategy used is based on derivatization 
of PLGA with the thioderivative of Neu5Ac as the starting 
material for the preparation of nanoparticles, and the second 
strategy is based on the synthesis of compounds potentially 
able to insert their lipophilic moiety into nonderivatized 
PLGA nanoparticles during their preparation and display 
their hydrophilic moiety (Neu5Ac) on their surface.131International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Transferrin receptors are overexpressed by 2–10-fold 
in most tumor cells, and thus, transferrin and/or transferrin 
antibodies may be used for targeting drugs to tumor cells.125 
Zheng et al synthesized transferrin-conjugated lipid-coated 
PLGA nanoparticles carrying the aromatase inhibitor, 
7-(4-amino) phenylthio-1, 4-androstadiene-3, 17-dione. The 
aromatase inhibition activity of the nanoparticles was evalu-
ated in a SKBR-3 breast cancer cell line. The IC50 value of the 
nanoparticles incorporating transferrin ranged from 0.77 to 
1.21 nM, and the IC50 value of the nanoparticles ranged from 
1.90 to 3.41 nM (n = 3). These results suggest that the aromatase 
inhibition activity of the transferrin nanoparticles was enhanced 
relative to that of the nontargeted nanoparticles, which was 
attributable to transferrin receptor-mediated uptake.132
The αvβ3 integrin is an endothelial cell receptor for extra-
cellular matrix proteins harboring the arginine-  glycine-aspartic 
acid (RGD) sequence.126 Wang et al conjugated doxorubicin 
to PLGA, and the nanoparticle surfaces were then linked with 
PEG and the RGD peptides to achieve both passive and active 
targeting functions. The nanoparticle targeting ability was 
enhanced via strong affinity to various integrin-expressing 
cancer cells, and much less affinity to low integrin-expressing 
cancer cells.133 Danhier et al showed that PEGylated PLGA-
based nanoparticles grafted with the RGD peptide or an RGD 
peptidomimetic, targeted the tumor endothelium and would 
enhance the antitumor efficacy of paclitaxel. They observed that 
RGD-grafted nanoparticles were more associated with human 
umbilical vein endothelial cells in vitro by binding to αvβ3 inte-
grin than were nontargeted nanoparticles, and they also demon-
strated the targeting of RGD and RGD peptidomimetic-grafted 
nanoparticles to tumor vessels, as well as effective retardation 
of transplantable liver tumor growth and prolonged survival 
times in mice treated by paclitaxel-loaded RGD nanoparticles 
when compared with nontargeted nanoparticles.134
The folate receptor is a highly specific tumor marker that 
is overexpressed in many human cancers. In addition, this 
receptor is absent in most normal tissues, so is frequently 
exploited for drug-targeting purposes. With the proper 
design, folate-drug conjugates display high-affinity proper-
ties which enable them to bind rapidly to the folate receptor 
and become internalized via an endocytic process.125
Yoo and Park prepared biodegradable polymeric micelles 
self-assembled from a diblock copolymer of PLGA and PEG 
to achieve delivery of doxorubicin to the folate receptor. They 
showed higher cytotoxicity to the folate-conjugated mixed 
micelles than for free doxorubicin, suggesting that folate 
  receptor-mediated endocytosis of micelles plays an important 
role in transporting an increased amount of doxorubicin into 
cancer cells. In   addition, in vivo animal experiments using a nude 
mouse xenograft model demonstrated that, when systemically 
administered, tumor volume was significantly reduced.135
In another study, Zhang et al synthesized doxorubicin-
loaded folate-decorated PLGA-vitamin E TPGS nanoparti-
cles for targeted chemotherapy to folate receptor-rich tumors. 
Table 3 Summary of targeted polylactide-co-glycolide nanoparticles
Layer Targeting moiety Anticancer drug Size (nm) Reference
Lectin Paclitaxel 330.7 ± 2.9 52
Sialic acid N-acetylneuraminic acid (Neu5AC) ∼70 131
egg 
phosphatidylcholine
Transferrin Aromatase inhibitor 170.3 ± 7.6 132
and DOPe (7α-APTADD)
vitamin e TPGS Folate Doxorubicin ∼350 136
PeG Folate Doxorubicin 104 ± 11.5 135
PeG Folate Docetaxel 216 ± 18 50
PeG Biotin Paclitaxel and tariquidar/siRNA ∼240 143,144
Polylysine SM5–1 single chain antibody Paclitaxel 129 ± 5.2 145
Mab against soluble membrane proteins  
of MCF-7
320–360 146
PeG cRGD Doxorubicin 423 ± 16.6 133
PeG RGD and RGD-peptidomimetic Paclitaxel 138 ± 3, 146 ± 2 134
epidermal growth factor receptor antibody Rapamycin ∼287 147
Trastuzumab Paclitaxel 312.3 ± 8.2 148
Anti-HeR 2 Fab’ Pseudomonas exotoxin 
(Pe38 KDeL)
124.2 ± 21.2 149
PeG A10 PSMA aptamer Docetaxel ∼180 150
PeG A10 PSMA aptamer Cisplatin ∼140 151
Abbreviations: PSMA, prostate-specific membrane antigen; PEG, polyethylene glycol; Mab, monoclonal antibody; RGD, arginine-glycine-aspartic acid sequence; DOPE, 
dioleoyl phosphatidylethanolamine; vitamin e TGPS, α-tocopheryl polyethylene glycol l000 succinate.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Their research showed that the TPGS-folate uptake was 1.5 
and 1.7 times higher in MCF-7 and C6 cells, respectively, 
as compared with nanoparticles with no TPGS-folate com-
ponent after 30 minutes of incubation.136
The authors of the present study produced docetaxel nano-
particles by using PLGA-PEG-folate conjugates for folate 
receptor-targeted anticancer delivery. The folate receptor-targeted 
nanoparticles showed greater intracellular uptake in folate recep-
tor-positive cancer cells (SKOV3) in comparison with the non-
targeted nanoparticles, indicating that a folate receptor-mediated 
endocytosis mechanism could have a role in the cellular uptake 
of nanoparticles.50 In another study, the same research group 
studied the use of PLGA-PEG-folate nanoparticles containing 
SN-38 (7-ethyl-10-hydroxy camptothecin). These folate receptor-
targeted nanoparticles showed greater cytotoxicity against cancer 
cells than nontargeted SN-38 nanoparticles.
Biotin is an essential micronutrient for normal cellular 
functions (eg, biosynthesis of fatty acids, gluconeogenesis), 
growth, and development. Humans and other mammals   cannot 
synthesize biotin and thus must obtain it from exogenous 
sources via intestinal absorption. Rapidly dividing cells, such 
as cancer cells, have a voracious appetite for certain vitamins, 
including biotin, vitamin B12, and folate. Biotin levels have 
been found to be significantly higher in some cancer cells 
compared with normal tissue.137 Interestingly, tumor cell lines, 
including ovarian and colorectal, which overexpress receptors 
involved in folate or vitamin B12 uptake also show overex-
pression of biotin receptors.138 Accordingly, several research 
groups have tested different biotinylated chemotherapeutic 
agents for cancer cell-specific drug delivery.139–142
Patil et al investigated simultaneous targeted delivery of 
paclitaxel with tariquidar (a third-generation P-glycoprotein 
modulator) using PLGA nanoparticles to overcome tumor 
drug resistance. Nanoparticles were surface-functionalized 
with biotin for active tumor targeting.143 In the same study, this 
group used small interfering RNA instead of tariquidar to silence 
expression of the P-glycoprotein efflux transporter in Balb/c 
mice bearing JC (mammary adenocarcinoma) tumors. Growth 
in tumor volume and survival were monitored on a regular 
basis. Biotin-conjugated nanoparticles demonstrated more tumor 
growth inhibition than the nontargeted nanoparticles.144
Antigen–antibody interaction
In recent years, overexpressing cancer-specific antigens have 
become an important tool in developing different delivery 
technologies for cancer treatment. The advent of monoclonal 
antibody technology in the 1970s and the development of 
genetically engineered derivatives in the 1980s, along with 
technological advances in the bulk production of monoclonal 
antibodies, have led to a number of clinical studies evaluat-
ing the efficacy of cancer-specific monoclonal antibodies 
in targeted drug delivery systems. The overexpression of 
receptors and antigens in human cancers also helps efficient 
uptake via receptor-mediated endocytosis. Moreover, due to 
their transformed nature, tumor cells overexpress many new 
proteins in comparison with normal cells, and these mark-
ers may be exploited for active drug targeting.125 Kou et al 
developed paclitaxel-loaded PLGA nanoparticles coated 
with cationic SM5-1 single-chain antibody. Nonradioactive 
cell proliferation assay demonstrated that targeted nanopar-
ticles had significantly better in vitro cytotoxicity against 
  Ch-hep-3 human hepatocellular cancer cells than nontargeted 
paclitaxel-loaded PLGAnanoparticles.145
Kocbek et al prepared PLGA immunonanoparticles for 
targeting invasive epithelial breast tumor cells. The monoclo-
nal antibody was prepared against soluble membrane proteins 
of MCF-7 human invasive ductal breast carcinoma and was 
attached to the nanoparticle surface either covalently or nonco-
valently. These nanoparticles were more likely to attach to the 
targeted cells than the noncoated nanoparticles. In coculture 
of MCF-10A neoT and Caco-2 cells, immunonanoparticles 
entered only MCF-10A neoT cells, while noncoated nano-
particles were taken up by both cell types, indicating specific 
targeting by the immunonanoparticles.146
The human epidermal receptor (HER) family of receptor 
tyrosine kinases offers two highly upregulated targets on 
tumor cell surfaces. These receptor tyrosine kinases, epider-
mal growth factor receptor and human epidermal receptor-2 
(HER2), are known to mediate a cell signaling pathway for 
growth and proliferation in response to binding of the growth 
factor ligand.125 Achraya et al prepared and characterized 
rapamycin-loaded PLGA nanoparticles so that their surfaces 
were modified with antibodies to the epidermal growth fac-
tor receptor, highly expressed on breast cancer cells, and 
improved the cytotoxicity of nanoparticles in a malignant 
MCF7 breast cancer cell line. IC50 doses, determined by MTT 
assay, showed superior antiproliferative activity of antibody-
conjugated rapamycin-loaded nanoparticles compared with 
the unconjugated nanoparticles and native rapamycin due 
to higher cellular uptake by malignant breast cancer cells. 
The molecular basis of apoptosis, studied by Western blot-
ting, revealed the involvement of a cytoplasmic protein in 
activating the programmed cell death pathway. Thus, it was 
concluded that epidermal growth factor receptor antibody-
conjugated rapamycin-loaded nanoparticles provide efficient 
and targeted delivery of anticancer drugs.147International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Trastuzumab, approved by the Food and Drug Admin-
istration, is amonoclonal antibody designed to antagonize 
HER2 function, and has been used as a targeting moiety 
in various nanoparticle systems.126 Sun et al investigated 
a nanoparticle formulation containing PLGA-montmoril-
lonite and trastuzumab for targeted breast cancer chemo-
therapy, with paclitaxel as a model anticancer drug. The 
in vitro drug release from this nanoparticle formulation 
showed a biphasic drug-release pattern, with a moder-
ate initial burst release followed by a sustained release 
profile.148 Gao et al developed Pseudomonas exotoxin 
(PE38KDEL)-loaded PLGA nanoparticles conjugated 
with Fab’ fragments (rhuMAbHER2) from a humanized 
anti-HER2 monoclonal antibody   (PE-NP-HER). Compared 
with nontargeted nanoparticles lacking anti-HER2 Fab’, 
PE-NP-HER specifically bound to and was sequentially 
internalized into HER2-overexpressing breast cancer cells, 
which resulted in significant cytotoxicity in vitro. Notably, 
PE-NP-HER was of low immunogenicity in the develop-
ment of anti-PE38KDEL-neutralizing antibodies, and was 
less susceptible to inactivation by anti-PE38KDEL antibod-
ies compared with PE-HER.149
Aptamer-mediated targeting
Aptamers are DNA or RNA oligonucleotides (short DNA 
or RNA oligonucleotide ligands) capable of binding to 
target antigens with high affinity and specificity, and are 
analogous to antibodies.125 The group led by Farokhzad and 
Langer150,151 investigated the targeting potential of aptamers 
specific to the extracellular domain of the prostate-specific 
membrane antigen (PSMA). Farokhzad et al developed 
180 nm docetaxel-encapsulated nanoparticles using a PLGA-
block-PEG copolymer surface-functionalized with the A10 
20-fluoropyrimidine RNA aptamers that recognize PSMA. 
Their results showed significant enhancement of the cellular 
toxicity of the functionalized nanoparticles in vitro as com-
pared with the nontargeted nanoparticles lacking the PSMA 
aptamer. In addition, after a single intratumoral injection 
of docetaxel-aptamer bioconjugate nanoparticles, complete 
tumor reduction was observed in five of seven LNCaP 
xenograft nude mice, and 100% survival was observed as 
compared with mice treated with docetaxel nanoparticles 
alone. They also studied the biodistribution of the nano-
particles in aLNCaP (PSMA+) xenograft mouse model of 
prostate   cancer.   Surface functionalization of the nanoparticles 
with A10 PSMA aptamer significantly enhanced (3.77-fold 
increase at 24 hours in nanoparticle aptamer of injected dose 
per gram of tissue) the delivery of nanoparticles to tumors 
versus equivalent nanoparticles   lacking the A10 PSMA 
aptamer.150
In another study, Dhar et al also used PLGA-b-PEG 
nanoparticles with PMSA-targeting aptamers on the surface 
as a vehicle for the platinum (IV) compound, c, t, c-[Pt(NH3)
(2)(O2CCH2CH2CH2CH2CH3)(2)Cl-2], as a strategy 
to deliver cisplatin to prostate cancer cells. A comparison 
between the cytotoxic activities of Pt(IV)-encapsulated 
PLGA-b-PEG nanoparticles with the PSMA aptamer on the 
surface (Pt-NP-Apt), cisplatin, and the nontargeted Pt(IV)-
encapsulated nanoparticles against human PSMA overex-
pressing LNCaP and PSMA(−) PC3 cancer cells revealed 
significant differences. The effectiveness of PSMA-targeted 
Pt-NP-Apt nanoparticles against the PSMA (+) LNCaP cells 
was significantly greater than that of free cisplatin.151
Conclusion
Current polymeric nanocarrier technologies have demon-
strated remarkable advantages for cancer therapy when 
compared with conventional drugs. Among the polymers 
utilized to date, PLGA is very promising for the preparation 
of novel anticancer drug delivery systems due to its desir-
able characteristics, including good biodegradability and 
biocompatibility. PLGA nanoparticles can achieve tumor-
targeted drug delivery via passive targeting based on the 
enhanced permeation and retention effect, or active targeting 
by an appropriate ligand, which improves antitumor efficacy 
and reduces toxicity on healthy tissues. For further advance-
ment, it will be necessary to focus more research attention 
on the pharmacokinetics, biodistribution, and safety of these 
novel drug delivery systems.
Development of multifunctional PLGA nanoparticles 
containing specific ligands for active targeting, and multiple 
drugs for synergistic anticancer effects and overcoming 
drug resistance, will provide a versatile and straightforward 
approach to improving chemotherapy. Combined therapeutic 
and diagnostic (theranostic) nanoparticles will be another 
potential future direction. In this case, theranostic PLGA 
nanoparticles will be detected in tumors by using a diagnos-
tic agent. These nanoparticles can modulate their responses 
based on changes in the environment. When imaging shows 
maximum nanoparticle accumulation in tumor tissue, physi-
cal sources, such as light or heat, can be applied to modify 
nanoparticle drug-releasing activity.
Lastly, despite significant progress so far, a large gap 
between the cost of preparing PLGA nanoparticles and that 
of conventional delivery systems is seen as an impediment 
to their commercial application. Until now, most of the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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methods reported for preparation and surface modifica-
tion of PLGA nanoparticles have involved small batches. 
Scale-up to large production volumes will certainly introduce 
additional challenges. As a result, the preparation process 
for PLGA nanoparticles needs to be further developed to 
achieve the reproducibility and scalability necessary in the 
marketplace.
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